Peptic ulcer esophagogastroduodenoscopy
|
Peptic ulcer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Surgery |
|
Case Studies |
|
2017 ACG Guidelines for Peptic Ulcer Disease |
|
Guidelines for the Indications to Test for, and to Treat, H. pylori Infection |
|
Guidlines for factors that predict the successful eradication when treating H. pylori infection |
|
Guidelines to document H. pylori antimicrobial resistance in the North America |
|
Guidelines for evaluation and testing of H. pylori antibiotic resistance |
|
Guidelines for when to test for treatment success after H. pylori eradication therapy |
|
Guidelines for penicillin allergy in patients with H. pylori infection |
|
Peptic ulcer esophagogastroduodenoscopy On the Web |
|
American Roentgen Ray Society Images of Peptic ulcer esophagogastroduodenoscopy |
|
Risk calculators and risk factors for Peptic ulcer esophagogastroduodenoscopy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ;Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]
Overview
Peptic ulcer esophagogastroduodenoscopy
American College of Gastroenterology (ACG) guidelines 2017 for the treatment of H pylori infection (HPI) include the following recommendations for testing for H pylori:[1]
- Active or past history of peptic ulcer disease.
- Low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma
- Confirmed history of PUD (not previously treated for H. pylori)
- Long-term therapy with nonsteroidal anti-inflammatory agents (NSAIDs) and low-dose aspirin
- Unexplained iron deficiency anemia following standard workup
- Idiopathic thrombocytopenic purpura
Algorithm for the Approach to Dyspepsia
| Age ≥ 55 or ⊕ alarm features*? | |||||||||||||||||||||||||||||||||||||
| YES | NO | ||||||||||||||||||||||||||||||||||||
| Endoscopy | H. pylori prevalence? | ||||||||||||||||||||||||||||||||||||
| High | Low | ||||||||||||||||||||||||||||||||||||
| Test-and-treat strategy ± acid suppression | Acid suppression trial | ||||||||||||||||||||||||||||||||||||
| If eradication therapy is indicated | |||||||||||||||||||||||||||||||||||||
| Clarithromycin resistance ≥ 20% | Clarithromycin resistance < 20% | ||||||||||||||||||||||||||||||||||||
| Quadruple or sequential therapy | PCA or PCM or Bismuth quadruple therapy | ||||||||||||||||||||||||||||||||||||
| PLA | Bismuth quadruple therapy or PLA | ||||||||||||||||||||||||||||||||||||
| Adjust Rx per susceptibility test | |||||||||||||||||||||||||||||||||||||
| Consider endoscopy if treatment fails | |||||||||||||||||||||||||||||||||||||
- Alarm symptoms-unexplained weight loss, progressive dysphagia, odynophagia, recurrent vomiting, family history of gastrointestinal cancer, overt gastrointestinal bleeding, abdominal mass, iron deficiency anemia, or jaundice[2]
References
- ↑ "www.nature.com" (PDF).
- ↑ Bowrey DJ, Griffin SM, Wayman J, Karat D, Hayes N, Raimes SA (2006). "Use of alarm symptoms to select dyspeptics for endoscopy causes patients with curable esophagogastric cancer to be overlooked". Surg Endosc. 20 (11): 1725–8. doi:10.1007/s00464-005-0679-3. PMID 17024539.